Anzeige
❌
Mehr »
Freitag, 09.10.2026 - Börsentäglich über 12.000 News
Elevate Sercive Group: Neue Expertise für den nächsten Wachstumsschritt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OR

WKN: A2PA31 | ISIN: US68621F1021 | Ticker-Symbol: 2PQ
Tradegate
08.10.26 | 15:31
1,160 Euro
+1,75 % +0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ORGANOGENESIS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ORGANOGENESIS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1301,16009:56
1,1301,15008:04

Aktuelle News zur ORGANOGENESIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.Organogenesis forecasts 2026 revenue of $179M-$215M amid June restructuring expected to cut $18M annually15
06.08.Organogenesis Holdings schließt 'At-the-Market'-Vertriebsvereinbarung über bis zu 75 Mio. US-Dollar ab14
06.08.Organogenesis Holdings Inc. - 8-K, Current Report2
06.08.Organogenesis Holdings GAAP EPS of -$0.77 misses by $0.42, revenue of $42.8M misses by $11.45M1
27.07.Organogenesis reports positive trial results for wound care product1
ORGANOGENESIS Aktie jetzt für 0€ handeln
27.07.Organogenesis Holdings Inc.: Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity in the Most Challenging and Complex Venous Leg Ulcers1
15.07.Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt
09.07.Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 20261
06.07.FDA accepts Organogenesis' application for knee osteoarthritis treatment1
06.07.Organogenesis Holdings Inc.: Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu for the Management of Symptomatic Knee Osteoarthritis341CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical...
► Artikel lesen
16.06.Organogenesis Holdings Inc. - 8-K, Current Report2
28.05.Truist initiates Organogenesis stock at Hold on reimbursement shifts1
08.05.BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds2
08.05.Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery1
07.05.Organogenesis Holdings Inc. - 8-K, Current Report-
28.04.Organogenesis completes biologics license application for knee OA2
28.04.Organogenesis Holdings Inc.: Organogenesis Completes Rolling Submission of Biologics License Application for ReNu393CANTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization...
► Artikel lesen
06.04.Organogenesis Holdings Inc.: Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain253Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...
► Artikel lesen
23.12.25Organogenesis Holdings Inc.: Organogenesis Announces Initiation of Biologics License Application for ReNu461CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...
► Artikel lesen
15.12.25Organogenesis Holdings Inc.: Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain242Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1